Drugs in development for non-alcoholic steatohepatitis (NASH) threaten the same kind of cost burden to payers as have the newer hepatitis C drugs, according to OptumRx Inc. Pipeline and Drug Surveillance Manager Farrah Wong.
“I’m often asked what I think is going to be the next hepatitis C class” in terms of cost. “It’s...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?